[1] 朱疆依,韩英.关于胆汁淤积性肝病诊断的几点探讨. 实用肝脏病杂志,2016,19:647-649 [2] 胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志,2016;19:2-12 [3] Cao XX, Gao YQ, Zhang WH, et al.Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai. Chin J Hepatol,2015,23(8):569-573. [4] Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury - what is the link? J Hepatol,2017,67:619-631. [5] Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr,2018,18:71-87. [6] Xiao Liu, Yan Wang. An overview of bile acid synthesis and its physiological and pathological functions. Hereditas (Beijing),2019,41(5):365-374. [7] Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects of Med,2017,56:45-53. [8] Virani S, Akers A, Stephenson K, et al. Comprehensive review of molecular mechanisms during cholestatic liver injury and cholangiocarcinoma. J Liver, 2018,7(3):321-325. [9] Gujral JS, Farhood A, Bajt ML, et al. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology,2003,38:355-363. [10] Ding L, Yang L, Wang Z, et al. Bile acid nuclear receptor fxr and digestive system diseases. Acta Pharm Sin B,2015,5:135-144. [11] Marin JJ, Macias RI, Briz O, et al. Bile acids in physiology, pathology and pharmacology. Curr Drug Metab,2015,17:4-29. [12] 周学谦, 陈文生. 胆汁淤积的分子机制与治疗靶点. 内科理论与实践,2018,13:388-393. [13] Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (slc10a1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype. Hepatology,2015,61:260-267. [14] Cai SY, Boyer JL. Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflamm Cell Signal,2017,4:327-233. [15] Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: A clear and present danger. Physio Rev,2010,90:1165-1194. [16] Woolbright BL, Antoine DJ, Jenkins RE, et al. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol,2013,273:524-531. [17] Woolbright BL, Dorko K, Antoine DJ, et al. Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. Toxicol Appl Pharmacol,2015,283:168-177. [18] Woolbright BL, Jaeschke H. Inflammation and cell death during cholestasis: The evolving role of bile acids. Gene Expr,2019,19:215-228. [19] Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis. Am J Patho,2011,178:175-186. [20] Woolbright BL, Jaeschke H. Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol,2012,18:4985-4993. [21] Cai SY, Boyer JL. The role of inflammation in the mechanisms of bile acid-induced liver damage. Dig Dis,2017,35:232-234. [22] Cai SY, Ouyang X, Chen Y, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight,2017,2:e90780. [23] Luyendyk JP, Kassel KM, Allen K, et al. Fibrinogen deficiency increases liver injury and early growth response-1 (egr-1) expression in a model of chronic xenobiotic-induced cholestasis. Am J Patho,2011,178:1117-1125. [24] Zhang Y, Hong JY, Rockwell CE, et al. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int,2012,32:58-69. [25] Aranda JF, Reglero-Real N, Marcos-Ramiro B, et al. Myadm controls endothelial barrier function through erm-dependent regulation of icam-1 expression. Mol Bioln Cell,2013,24:483-494. [26] Li M, Mennone A, Soroka CJ, et al. Na(+) /h(+) exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury. Hepatology, 2015,62:1227-1236. [27] Murray PJ. Macrophage polarization. Annu Rev Physiol, 2017,79:541-566. [28] Sato K, Hall C, Glaser S,et al. Pathogenesis of kupffer cells in cholestatic liver injury. Am J Patho, 2016,186:2238-2247. [29] Calmus Y, Poupon R. Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases. Clin Res Hepatol Gastroenterol, 2014,38:550-556. [30] Perino A, Schoonjans K. Tgr5 and immunometabolism: Insights from physiology and pharmacology. Trends Pharmacol Sci, 2015,36:847-857. [31] Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol, 2017,66:1300-1312. [32] Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: From pathogenesis to novel therapeutic strategies. Cell Mol Immunol, 2016,13:316-327. [33] Duwaerts CC, Sun EP, Cheng CW, et al. Cross-activating invariant nkt cells and kupffer cells suppress cholestatic liver injury in a mouse model of biliary obstruction. PloS one,2013,8:e79702. [34] Chuang YH, Lian ZX, Yang GX, et al. Natural killer t cells exacerbate liver injury in a transforming growth factor beta receptor ii dominant-negative mouse model of primary biliary cirrhosis. Hepatology ,2008,47:571-580. [35] Cheng CW, Duwaerts CC, Rooijen N, et al. Nk cells suppress experimental cholestatic liver injury by an interleukin-6-mediated, kupffer cell-dependent mechanism. J Hepatol, 2011,54:746-752. |